<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04242810</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00102980</org_study_id>
    <nct_id>NCT04242810</nct_id>
  </id_info>
  <brief_title>Effects of rTMS on Human Brain Activity</brief_title>
  <official_title>Effects of rTMS on Human Brain Activity Measured With fMRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate how repetitive transcranial magnetic stimulation&#xD;
      (rTMS) affects brain networks measured by functional magnetic resonance imaging (fMRI).&#xD;
&#xD;
      Participants will undergo a screening that includes a psychiatric and medical history&#xD;
      screening, TMS and MRI safety screening, and urine screening. If participants pass the&#xD;
      screening procedure, they will be introduced to transcranial magnetic stimulation (TMS),&#xD;
      magnetic resonance imaging (MRI), and a task that involves viewing words, sentences, or&#xD;
      pictures. There will be up to seven visits and each visit will take less than 3 hours.&#xD;
&#xD;
      MRI can be dangerous for people that have medical devices, metal objects, or metal debris in&#xD;
      their bodies. TMS procedures are associated with a very low risk of seizures,&#xD;
      &quot;muscle-tension&quot; type headache, ear damage, numbness of the face, fainting, dizziness, memory&#xD;
      impairment, trouble concentrating, and acute mood changes. This study will use only levels of&#xD;
      TMS that are within safety guidelines. There is also a risk of potential loss of&#xD;
      confidentiality.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of a rTMS session on the performance for a memory task, as measured by accuracy (in percentage of correct responses)</measure>
    <time_frame>up to 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>An effect of a rTMS session on the performance for a memory task, as measured by reaction time (in ms)</measure>
    <time_frame>Time frame: up to 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>An effect of a rTMS session on fMRI brain representation for a memory task, as measured by BOLD signal</measure>
    <time_frame>up to 1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Repetitive Transcranial Magnetic Stimulation (rTMS)</condition>
  <arm_group>
    <arm_group_label>Active rTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rTMS applied over memory task-based brain target</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham rTMS applied over memory task-based brain target</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rTMS</intervention_name>
    <description>TMS will be applied over task-based target at an intensity up of 130% rMT. The optimal coil placement during stimulation will be guided using the BrainSight neuronavigation system.</description>
    <arm_group_label>Active rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham rTMS</intervention_name>
    <description>An electrical sham coil that produces the same auditory and somatosensory stimulations, without a significant magnetic field, will be used as an active control.</description>
    <arm_group_label>Sham rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI scan</intervention_name>
    <description>Participants will undergo an MRI scan directly after rTMS stimulation that will last less than 120 minutes. During the scan, subjects will encode and retrieve object pictures.</description>
    <arm_group_label>Active rTMS</arm_group_label>
    <arm_group_label>Sham rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age restrictions: between 18-35 years old&#xD;
&#xD;
          -  Use of effective method of birth control for women of childbearing capacity.&#xD;
&#xD;
          -  Willing to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or recent (within the past 6 months) substance abuse or dependence, excluding&#xD;
             nicotine and caffeine (urine test)&#xD;
&#xD;
          -  Current serious medical illness (self-report)&#xD;
&#xD;
          -  History of seizure except those therapeutically induced by ECT (childhood febrile&#xD;
             seizures are acceptable and these subjects may be included in the study), history of&#xD;
             epilepsy in self or first degree relatives, stroke, brain surgery, head injury,&#xD;
             cranial metal implants, known structural brain lesion, devices that may be affected by&#xD;
             rTMS or MRI (pacemaker, medication pump, cochlear implant, implanted brain stimulator)&#xD;
&#xD;
          -  Subjects are unable or unwilling to give informed consent&#xD;
&#xD;
          -  Diagnosed any Axis I DSM-IV disorder (MINI, DSM-IV)&#xD;
&#xD;
        Subjects with a clinically defined neurological disorder including, but not limited to:&#xD;
&#xD;
          -  Any condition likely to be associated with increased intracranial pressure&#xD;
&#xD;
          -  Space occupying brain lesion.&#xD;
&#xD;
          -  History of stroke.&#xD;
&#xD;
          -  Transient ischemic attack within two years.&#xD;
&#xD;
          -  Cerebral aneurysm.&#xD;
&#xD;
          -  Dementia.&#xD;
&#xD;
          -  Parkinson's disease.&#xD;
&#xD;
          -  Huntington's disease.&#xD;
&#xD;
          -  Multiple sclerosis.&#xD;
&#xD;
          -  Increased risk of seizure for any reason, including prior diagnosis of increased&#xD;
             intracranial pressure (such as after large infarctions or trauma), or currently taking&#xD;
             medication that lowers the seizure threshold&#xD;
&#xD;
          -  Subjects with cochlear implants&#xD;
&#xD;
          -  Subjects not willing to tolerate the confinement associated with being in the MRI&#xD;
             scanner&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding (urine test)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Cabeza</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fang Wang</last_name>
    <phone>919-668-2299</phone>
    <email>fang.wang2012@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Fang Wang</last_name>
      <phone>919-668-2299</phone>
      <email>fang.wang2012@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

